SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trialSammy Huygens, Jarom Heijmans, Quincy Hofsink et al.|medRxiv|2022Cited by 1